Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291525 | 1.00 | KISS1R (0.48) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL9419755 | 0.81 | GRIK1 (0.41) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL9419756 | 0.81 | GRIK1 (0.41) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL11580371 | 0.80 | ALDH1A1 (0.41) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL2294922 | 0.79 | ALDH1A1 (0.39) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL2294924 | 0.79 | ALDH1A1 (0.39) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL2293073 | 0.78 | KISS1R (0.50) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL2293077 | 0.78 | KISS1R (0.50) | KISS1RALDH1A1TDP1CA2CYP2C19 | |
| SCHEMBL2335834 | 0.76 | ALDH1A1 (0.35) | KISS1RALDH1A1TDP1 | |
| SCHEMBL9152013 | 0.73 | NPSR1 (0.38) | KISS1RALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976512-B1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8003800-B2 | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1976512-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007080542-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | S1PR3, S1PR1, S1PR2 | KISS1R 277/4885ALDH1A1 1713/4885TDP1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.